C4 Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
C4 Therapeutics, Inc. (Ticker: CCCC) filed a Current Report on Form 8-K on April 10, 2026, regarding events occurring on April 9, 2026. The Company is incorporated in Delaware and its common stock trades on the Nasdaq Global Select Market.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes
On April 9, 2026, the Board of Directors approved an amendment to the Company's Second Amended and Restated By-laws. This amendment designates the United States District Court for the District of Massachusetts and the United States District Court for the District of Delaware as the exclusive forums for resolving complaints arising under the Securities Act of 1933, the Securities Exchange Act of 1934, or related rules, unless the Company consents in writing to an alternative forum. This change was made in response to recent amendments to the General Corporation Law of the State of Delaware.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. The primary risk disclosed relates to the legal jurisdiction for securities-related litigation, which is now restricted to specific federal courts in Massachusetts and Delaware.
Key Facts for Investor Verification
- The By-laws Amendment became effective immediately upon Board approval on April 9, 2026.
- Shareholders should review Exhibit 3.1 for the full text of the By-laws Amendment.
- This filing is a corporate governance update and does not reflect operational or financial performance.